Mike McCune, MD, PhD

Headshot of Mike McCune
User Profile Photo

Mike McCune, MD, PhD

User Profile Name
Head, HIV Frontiers Global Health Innovative Technology Solutions Bill & Melinda Gates Foundation
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Joseph ("Mike") McCune is a professor of medicine at the University of California, San Francisco (UCSF). He received his AB degree from Harvard College in 1975, his PhD degree from Rockefeller University in 1981, and his MD degree from Cornell University Medical College in 1982. He completed his residency in internal medicine in 1984 and did fellowship training in infectious diseases at UCSF. He is board certified in internal medicine. The McCune lab has been involved for many years in the analysis of HIV pathogenesis, prevention, treatment, and cure. Dr. McCune started to treat patients with HIV disease as a resident in internal medicine at UCSF in 1982 and has been involved in the HIV/AIDS research field ever since. This work included postdoctoral studies at Stanford, exploring the fusogenic properties of the HIV envelope protein and developing the first humanized mouse model (the SCID-hu mouse) capable of multilineage human hematopoiesis and receptive to infection with primary isolates of HIV. He then co-founded the companies SyStemix (in 1988) and Progenesys (and 1991), serving as Scientific Director and leading research efforts to find better ways – including antiviral medications and hematopoietic stem cell-based gene therapy – to treat HIV disease. In 1995, Dr. McCune returned to academia, first as an investigator at the Gladstone Institute of Virology and Immunology and then (from 2006-2016) as the Chief of the Division of Experimental Medicine (which he founded) at UCSF. Concomitantly, he was the founding PI (and Senior Associate Dean) of the Clinical and Translational Sciences Institute at UCSF (from 2005-08). In recent years, he has helped to form multidisciplinary, collaborative research teams to find a cure for HIV disease. Throughout this time, he has actively mentored graduate students and postdoctoral fellows, many of whom have gone on to successful careers in academia or biotech/pharma. Dr. McCune’s studies have led to the publication of over 200 peer-reviewed articles, and he is the holder of 20 patents and inventions. He is a member of many scientific and professional societies, including the American Society for Clinical Investigation, the American Association of Physicians, and the Henry Kunkel Society. He has served on the editorial boards of Virology and the Journal of the Acquired Immune Deficiency Syndrome. He was awarded the Elizabeth Glaser Pediatric AIDS Foundation Scientist Award in 1996, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research in 2000, a MERIT Award from the NIH in 2001, the NIH Director’s Pioneer Award in 2004, and the Holly Smith Award for Exceptional Service to the School of Medicine in 2016. He was also selected to give the UCSF Academic Senate Faculty Research Lecture (on Translational Science) in 2013.
CTSI Profile Bio

Displaying 101 - 125 of 252

  1. Favre D, Stoddart CA, Emu B, Hoh R, Martin JN, Hecht FM, Deeks SG, McCune JM. HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood. 2011 Feb 17; 117(7):2189-99.
  2. Mold JE, Venkatasubrahmanyam S, Burt TD, Michaëlsson J, Rivera JM, Galkina SA, Weinberg K, Stoddart CA, McCune JM. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science. 2010 Dec 17; 330(6011):1695-9.
  3. Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, Loke P. IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med. 2010 Dec 01; 2(60):60ra88.
  4. Baum PD, Young JJ, Zhang Q, Kasakow Z, McCune JM. Design, construction, and validation of a modular library of sequence diversity standards for polymerase chain reaction. Anal Biochem. 2011 Apr 01; 411(1):106-15.
  5. Burt TD, Seu L, Mold JE, Kappas A, McCune JM. Naive human T cells are activated and proliferate in response to the heme oxygenase-1 inhibitor tin mesoporphyrin. J Immunol. 2010 Nov 01; 185(9):5279-88.
  6. Lee TH, Chafets DM, Biggar RJ, McCune JM, Busch MP. The role of transplacental microtransfusions of maternal lymphocytes in in utero HIV transmission. J Acquir Immune Defic Syndr. 2010 Oct; 55(2):143-7.
  7. Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807-10.
  8. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010 May 19; 2(32):32ra36.
  9. Kanwar B, Favre D, McCune JM. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS. 2010 Mar; 5(2):151-7.
  10. Swainson LA, Mold JE, Bajpai UD, McCune JM. Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1. J Immunol. 2010 Apr 01; 184(7):3639-47.
  11. Stoddart CA, Keir ME, McCune JM. IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog. 2010 Feb 19; 6(2):e1000766.
  12. Loke P, Favre D, Hunt PW, Leung JM, Kanwar B, Martin JN, Deeks SG, McCune JM. Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood. 2010 Apr 15; 115(15):e20-32.
  13. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune JM, Deeks SG. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010 Jan 29; 5(1):e8886.
  14. Cheng LE, Kanwar B, Tcheurekdjian H, Grenert JP, Muskat M, Heyman MB, McCune JM, Wara DW. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol. 2009 Jul; 132(1):124-31.
  15. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, Palermo R, Pandrea I, Miller CJ, Katze MG, McCune JM. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009 Feb; 5(2):e1000295.
  16. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog. 2009 Feb; 5(2):e1000296.
  17. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009 Mar 13; 284(11):6782-9.
  18. Lozano Reina JM, Favre D, Kasakow Z, Mayau V, Nugeyre MT, Ka T, Faye A, Miller CJ, Scott-Algara D, McCune JM, Barré-Sinoussi F, Diop OM, Müller-Trutwin MC. Gag p27-specific B- and T-cell responses in Simian immunodeficiency virus SIVagm-infected African green monkeys. J Virol. 2009 Mar; 83(6):2770-7.
  19. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, Lee TH, Nixon DF, McCune JM. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science. 2008 Dec 05; 322(5907):1562-5.
  20. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008 Nov 24; 205(12):2763-79.
  21. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009 Jan; 83(1):329-35.
  22. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A. 2008 Jun 24; 105(25):8718-23.
  23. Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D, McCune JM. Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol. 2008 Jun 15; 180(12):7907-18.
  24. Schweneker M, Favre D, Martin JN, Deeks SG, McCune JM. HIV-induced changes in T cell signaling pathways. J Immunol. 2008 May 15; 180(10):6490-500.
  25. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol. 2008 Jun; 82(11):5398-407.